Aclaris licenses anti-TSLP/IL4R biologics, raises $80M, appoints Davis as President/COO

Aclaris Therapeutics, Inc.

License deal: $30M upfront, $4.5M dev reimbursement, warrants for 14.3M shares at $0.00001, up to $920M milestones, royalties.
Private placement: 35.6M shares at $2.25 for $80M gross; closed Nov 19; led by Vivo Capital; cash runway into 2028.
Leadership additions: Hugh Davis as President/COO + Class III director; Steven Knapp EVP Regulatory & Quality.
Adopted 2024 Inducement Plan reserving 2M shares; Davis granted options for 375K shares, RSU for 107K shares.

item 1.01 item 3.02 item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Hugh Davis

Class III Director

ACRS · Aclaris Therapeutics, Inc.

Effective: 2024-11-18
Filed: November 18, 2024, 6:59 PM ET

The Board also appointed Dr. Davis to the Board, effective November 18, 2024, to serve as a Class III director

Role change

Neal Walker

President

ACRS · Aclaris Therapeutics, Inc.

Effective: 2024-11-18
Successor: Hugh Davis
Filed: November 18, 2024, 6:59 PM ET

In connection with Dr. Davis’s appointment, Neal Walker will no longer serve as the Company’s President but will continue to serve as the Company’s Interim Chief Executive Officer.

Appointed

Hugh Davis

President and Chief Operating Officer

ACRS · Aclaris Therapeutics, Inc.

Effective: 2024-11-18
Filed: November 18, 2024, 6:59 PM ET

On November 16, 2024, the board of directors (the “ Board ”) of the Company appointed Hugh Davis, Ph.D., as the Company’s President and Chief Operating Officer effective November 18, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Hugh Davis was appointed as Class III Director at Aclaris Therapeutics, Inc..

Action: appointed
Role: Class III Director

Exact text from the filing

The Board also appointed Dr. Davis to the Board, effective November 18, 2024, to serve as a Class III director

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Neal Walker changed role as President at Aclaris Therapeutics, Inc..

Action: will no longer serve role
Role: President

Exact text from the filing

In connection with Dr. Davis’s appointment, Neal Walker will no longer serve as the Company’s President but will continue to serve as the Company’s Interim Chief Executive Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Hugh Davis was appointed as President and Chief Operating Officer at Aclaris Therapeutics, Inc..

Action: appointed
Role: President and Chief Operating Officer

Exact text from the filing

On November 16, 2024, the board of directors (the “ Board ”) of the Company appointed Hugh Davis, Ph.D., as the Company’s President and Chief Operating Officer effective November 18, 2024.

View on SEC.gov

Aclaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-015838

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.